According to a report, a nasal spray that can fight coronavirus has been developed by researchers at the University of California, San Francisco. Researchers are currently working to clinically test and manufacture it.
The aerosol aerosol spray, called AeroNabs, is an antiviral drug aimed at blocking COVID-19, the researchers said in a statement, although it is not a cure. They added that it could be a good weapon against the new coronavirus until a vaccine is found, or a potential alternative for people who do not respond to the vaccine.
CHILDREN WITH VIRUS RISK CAN TAKE VIRUS MORE THAN 10 TO 100 TIMES AS ADULT: STUDY
“Much more effective than wearable personal protective equipment, we consider AeroNabs as a molecular form of PPE that could serve as an important deterrent until vaccines deliver. a more permanent solution for COVID-19, ”said Dr. Peter Walter. , professor of biochemistry and physiology at UCSF and Investigator of the Howard Hughes Medical Institute, in a press release.
“For those who cannot access or do not respond to the SARS-CoV-2 vaccine, AeroNabs could be a more permanent line of defense against COVID-19,” said Walter, who is also a co-inventor of AeroNabs. , added.
The scientists claimed in the release that they were inspired by nano bodies, like the antibodies found in llamas and camels.
“Although they act like antibodies found in the human immune system, the nanobodies offer several unique advantages for effective treatment against SARS-CoV-2,” co-patent. Aashish Manglik, MD, Ph.D., an assistant professor. pharmaceutical chemistry, in a statement.
The researchers explain that SARS-CoV-2 relies on mutant proteins to infect human cells.
“They are the key to allowing viruses to enter our cells,” they said.
The researchers explain that when the coronavirus is activated, the spiny receptors begin to attach to ACE2 inhibitors (ACE 2) found in human cells that line the nasal passages, lungs, and airways. . Coronavirus researchers recently told Fox News that this is the point of entry for the virus.
The authors explain in the report that they have developed “single domain antibodies (nanobodies) that are capable of disrupting the interaction between SARS-CoV-2 Spike and ACE2.” They were able to create synthetic nanobodies in the yeast surface and found that the nanobodies bind to the spikes and block the interaction of ACE2, thus preventing the virus from entering the host.
CORONAVIRUS: DOES YOUR BODY HAVE cells to recognize it and fight it?
The investigators explained in the press release that the most powerful nanoparticles functioned not only as a shell around the spike receptors, but also as a “molecular mousetrap, clamping on spikes.” in the closed, inactive state adds an additional layer of defense against the spike-in interaction – ACE2 leads to infection. “
The nanoparticles remained a strong antiviral SARS-CoV-2 when tested in aerosol form, according to the report. This means it can practically be used via an inhaler or a nasal spray that has a shelf life. This aerosol form could provide a “patient-friendly prophylactic agent and / or early infection to prevent the worst pandemic in a century,” the researchers said.